BSX

Boston Scientific

Fundamental data last updated:April 13, 2026

company profile

SECTOR

Healthcare

industry

Medical Devices

Exchange

NYSE

County of HQ

United States

Next Earnings Date

04/22/26

Business Summary

Boston Scientific generates cash by designing and selling specialized medical devices used in interventional procedures across cardiovascular, urology, and other high-acuity specialties. Its moat is built on physician relationships, regulatory approvals, entrenched hospital procurement channels, and iterative product innovation that raises switching costs. Once a device platform is embedded in clinical practice, replacement cycles, disposables, and complementary tools create recurring revenue streams. Scale allows it to spread R&D and compliance costs across a broad portfolio, reinforcing margins and sustaining competitive positioning in a highly regulated market.

VALUATION

P/E

31.9

Market Cap ($M USD)

$91,830

Forward P/E

15.8

PEG

1.4

PRICE TO SALES

4.6

PRICE TO BOOK

3.8

EV / EBITDA

19.9

5-Year Average P/E

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

$1.96

Next Year EPS Growth Estimate

$3.90

Next Year Revenue Growth Estimate

10.10%

Return on Equity (ROE)

12.00%

Operating Margin

19.80%

Debt-to-Equity

0.5

Piotroski F-Score

8

Altman Z-Score

3.9

Return on Invested Capital (ROIC)

9.30%%

Current Ratio

1.6

Quick Ratio

Gainseekers Quantitative Analysis

Summary

At 31.9x earnings with a Forward P/E of 15.8, the market is clearly pricing in a meaningful earnings ramp, and the 1.4 forward PEG suggests growth is coming at a reasonable price rather than a speculative premium. An Altman Z-Score of 3.9 signals low bankruptcy risk and strong balance sheet stability, reinforcing that this is not a fragile growth story. With a $91,830M market cap and solid profitability metrics, this looks more like a scaled compounder than a turnaround. The valuation is not deep value, but the compression from 31.9x to 15.8x forward earnings implies earnings acceleration that could justify accumulation under a disciplined GARP framework.

AI Exposure / Tech Reliance

As a Medical Devices company in Healthcare, Boston Scientific operates in a segment increasingly shaped by data integration, minimally invasive innovation, and device intelligence. The industry’s evolution toward AI-assisted diagnostics and procedural optimization supports durable demand for advanced devices. Companies embedded in clinical workflows tend to benefit from technology layering rather than disruption, making tech adaptation more additive than existential.

The Bull Case

A Piotroski F-Score of 8 is elite and signals operational strength, improving fundamentals, and disciplined financial management. ROIC at 9.30% alongside a 10.10% Return on Equity shows the company is generating respectable returns without excessive leverage, supported by a manageable 19.80% Debt/Equity ratio. Operating margins of 12.00% in a capital-intensive medical device business demonstrate pricing power and cost control. With a current ratio of 1.6 and an Altman Z-Score of 3.9, the balance sheet risk is contained, giving institutions confidence to accumulate a $91,830M name that still trades at a reasonable 1.4 PEG.

The Bear Case

The headline P/E of 31.9 is not cheap, and investors are implicitly betting that the drop to a 15.8 Forward P/E materializes through earnings delivery; any miss would compress the multiple fast. A PEG of 1.4 is reasonable but leaves limited margin of safety if growth slows, especially given only 12.00% operating margins. ROIC at 9.30% is solid but not exceptional, meaning capital efficiency is good, not dominant. The lack of a meaningful dividend (0.5 yield, no listed payout ratio) removes income support, and absent short interest data reduces visibility into potential downside pressure or contrarian signals.

Market Sentiment & Smart Money

Short Interest %

1.70%

Analyst Consensus

1.26

Average Analyst Price Target

$102.23

Institutional Ownership %

95.00%

1-Year Beta

0.33

Insider Buying % (6 Mo)

0.20%%

Distance to 52-Week High

56.40%%

Distance to 52-Week Low

102.00%%